US equities |
MU $969.48 ▲+4.38% META $612.41 ▼-1.25% SPCX $144.05 ▼-3.05% TSLA $400.11 ▼-1.80% SNDK $1,360.49 ▲+4.27% NVDA $217.80 ▼-0.06% SKHY $160.51 ▲+10.43% GOOGL $323.55 ▲+0.93%
FinancialContent

Schrodinger, Inc. - Common Stock (NQ:SDGR)

30.39 +3.68 (+13.75%)
Delayed Quote Updated: 10:50 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Schrödinger to Present at UBS Global Healthcare Conference
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Announce Third Quarter 2026 Financial Results on November 4
From Schrödinger
Via Business Wire
News headline image
Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
From Schrödinger
Via Business Wire
Schrodinger (NASDAQ:SDGR) Q2 Results Beat Expectations; Guidance Raised ↗
Via Chartmill
Schrödinger Inc (NASDAQ:SDGR) Q1 2026 Earnings: Revenue Beat Fails to Offset Loss Miss, Stock Slides ↗
Via Chartmill
Schrödinger Inc (NASDAQ:SDGR) Posts Q4 Earnings Beat Amid Strategic Software Model Shift ↗
Via Chartmill
Topics Earnings
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Schrödinger (SDGR) Q2 2026 Earnings Call Transcript ↗
AI co-scientist Bunsen drives productivity gains amid software model shift. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
AI Found an Influenza Target That Survives Viral Mutation
Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT) 
From Equity Insider
Via GlobeNewswire
News headline image
Schrodinger Q2 Earnings Call Highlights ↗
Schrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Schrödinger Reports Second Quarter 2026 Financial Results
From Schrödinger
Via Business Wire
News headline image
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
From Schrödinger
Via Business Wire
News headline image
Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
My Top 3 Biotech Stocks for May 2026 ↗
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Schrödinger (SDGR) Q1 2026 Earnings Transcript ↗
Schrödinger (SDGR) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Schrödinger Reports First Quarter 2026 Financial Results
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Participate in Upcoming Investor Conferences
From Schrödinger
Via Business Wire
News headline image
Schrödinger to Announce First Quarter 2026 Financial Results on May 5
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
News headline image
Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results
From Schrödinger
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >